Takeda Says Failed Norovirus Vaccine Study Supports Further Work
This article was originally published in The Pink Sheet Daily
Executive Summary
Norovirus vaccine missed primary endpoint in Phase I/II study highlighted at IDWeek, but did show activity in minimizing severity of infection. With tens of millions of cases every year in the U.S., the market would be large.